Navigation Links
Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/3/2010

SAN DIEGO, Nov. 3, 2010 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the third quarter of 2010.  For the quarter ended September 30, 2010, Orexigen reported a net loss of $14.6 million, or $0.31 per share attributable to common stockholders, as compared to a net loss of $14.4 million, or $0.33 per share attributable to common stockholders, for the third quarter of 2009.  As of September 30, 2010, Orexigen had $8.4 million in cash and cash equivalents and an additional $92.2 million in marketable securities, for a total of $100.6 million.

"We had previously set three major goals for the Contrave® program:  partnership, approval and launch," said Michael Narachi, President and CEO of Orexigen. "In the third quarter, we succeeded in executing a North American partnership agreement with Takeda Pharmaceutical Company Limited, which we believe will further our goal of a strong, focused, U.S. market entry for Contrave, if approved. With a partnership in place our attention continues to be on the regulatory review process for Contrave."

Total operating expenses for the third quarter of 2010 were $14.8 million compared to $14.2 million for third quarter of 2009.  The increase in operating expenses primarily reflects an increase in license fees, stock-based compensation expense and salaries and personnel related costs, offset partly by a reduction in research and development expenses related to the completion of Contrave Phase 3 clinical trials and completion of the Phase 2 clinical trial for Empatic™. Notably, operating expenses in the third quarter included $3.0 million in milestones paid to third parties related to the execution of the Takeda collaboration.

Conference Call Today at 5:00 p.m. Eastern Time
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
2. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
3. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
6. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
7. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
8. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
9. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
10. Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
11. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... VIENNA , September 3, 2014 /PRNewswire/ ...   to be located in the ... Nabriva Therapeutics AG, a biotechnology company ... antibiotics for the treatment of serious infections caused by ... Broom as Chief Executive Officer (CEO). Current CEO Ralf Schmid will ...
(Date:9/3/2014)... ,    ~ Clinical ... Kiadis Pharma B.V. ("Kiadis Pharma", ... developing T-cell immunotherapy treatments for blood cancers, today announces ... PhD, as its Chief Medical Officer. Jeroen ... Biosciences. Prior to that he was VP Medical Affairs ...
(Date:9/3/2014)... BUDAPEST, Hungary , Sept. 3, 2014 /PRNewswire/ ... "Palatin") and Gedeon Richter Plc. (hereinafter: "Richter") announced ... license agreement to co-develop and commercialize bremelanotide for ... Union, other European countries and additional selected countries.  ... a strong focus in female health and annual ...
Breaking Medicine Technology:Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer 2Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer 3Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 2Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 3Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 5Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 2Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 3Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 4Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 5
... Sigma-Aldrich Corporation (NASDAQ: SIAL ) will ... KeyBanc Capital Markets 2011 Basic Materials ... InterContinental, Boston, MA, presenting at 9:00 AM (Eastern). ... at the Grand Hyatt, New York, NY, presenting at ...
... SimonMed and Cox Business have partnered to make a ... patients in the Valley and across the state at ... is the first dedicated outpatient offering of breast tomosynthesis ... in Scottsdale. Sub-specialty trained radiologists at SimonMed ...
Cached Medicine Technology:Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences 2SimonMed and Cox Business Bring Breast Tomosynthesis to Arizona 2
(Date:9/3/2014)... Angeles, CA (PRWEB) September 03, 2014 ... is hosting a free webinar called “Google Hates ... the live presentation will reveal common problems that render ... – and offer strategies to overcome them. , The ... 10th, beginning at 11am PST (2 pm EST), and ...
(Date:9/3/2014)... Viejo, California (PRWEB) September 03, 2014 ... new ProStatic Lesson from Pixel Film Studios. , “ProStatic ... TV and VCR static to special effect artist,” said ... users customizable options to create the static distortion based ... static effects of an old television or VCR in ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Londi Palmisano, ... to offer an innovative solution for people looking for ... muscles of the back and upper body. In a ... really innovative and functional design for promoting increased flexibility ... body weight, and a gentle rocking motion. , Then, ...
(Date:9/3/2014)... Mila Carlson, PhD, RN, CLNC, CNLCP, ... healthcare provider. Celebrating 5 years of successful service ... of the National Alliance of Certified Legal ... Consultants, American Association of Legal Nurse Consultants-Greater Chicago ... Care Planners. , Dr. Carlson’s background is ...
(Date:9/3/2014)... Seattle, Wa (PRWEB) September 03, 2014 ... report created by Nguyen Do on the site Vkool.com, ... on health and beauty, and provides detailed instructions on ... of this report, people will discover some reasons to ... soothes chapped lips ,     It may protect against ...
Breaking Medicine News(10 mins):Health News:Fred Joyal Webinar Warns Dentists: Google Hates Your Website 2Health News:Fred Joyal Webinar Warns Dentists: Google Hates Your Website 3Health News:A New ProStatic Lesson was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Body Archer's Solution for Perfect Back Stretching Sparks Interest Among Health Care Pros 2Health News:Mila Carlson & Associates, P.C., Celebrates 5 Years of Excellence in Business Serving as a Legal Nurse Consultant and Nurse Life Care Planner 2Health News:Mila Carlson & Associates, P.C., Celebrates 5 Years of Excellence in Business Serving as a Legal Nurse Consultant and Nurse Life Care Planner 3Health News:“Health And Beauty Benefits Of Olive Oil,” a New Report on Vkool.com, Reveals to People the Benefits of Olive Oil on Health and Beauty 2Health News:“Health And Beauty Benefits Of Olive Oil,” a New Report on Vkool.com, Reveals to People the Benefits of Olive Oil on Health and Beauty 3
... found the survival rate of non-small-cell lung cancer ... adjuvant chemotherapy. Cisplatin is an anti-neoplastic medication that ... slows their growth and spread in the body. ... receive either three or four cycles of cisplatin-based ...
... the world's first epilepsy drug, an Australian neurologist says.// ... a mild sedative, taken either as a herbal infusion ... form. ,But the Italian author Fabio Colonna first ... botanical work Phytobasanos. ,Colonna said he had controlled ...
... dads who have children at an older age may ... in life. ,Researchers based their analysis on ... between 1989 and 2001 with a diagnosis of schizophrenia ... strong association between the fathers' age at conception and ...
... use stomach-acid suppressive medications for indigestion or gastroesophageal reflux ... of developing pneumonia .// ,The use of ... infections, as stomach acidity is a major defense mechanism ... than 364,000 patients who did and did not use ...
... say they have found that the drug toremifene, also ... decreased patients' cancer incidence after 12 months of treatment. ... but the 20-milligram dose had the greatest effect. ... neoplasia, characterized by abnormal cells in the lining of ...
... that sleep disorders may be linked to other medical ... neuromuscular conditions, and psychiatric problems. ,Researchers conducted a ... apnea also had ADD. Results also show a high ... showed some of these patients also suffered severe memory ...
Cached Medicine News:Health News:Valerian was first epilepsy drug 2
Double ended lasik spatula with flattened tip for lifting and smoothing the corneal flap. The sharp tip is useful to outline a previous flap in preparation for retreatment....
Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 150o....
Double ended with 0.5 mm x 10 mm and 0.5 mm x 15 mm blades. Both blades gently curved. Square serrated handle with polished finish. Most popular size or model....
Medicine Products: